DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair, With death on the horizon, nothing will not stop me except God................DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 25Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK GENERICS at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution
Showing posts with label WO2011069761. Show all posts
Showing posts with label WO2011069761. Show all posts

Tuesday, 23 December 2014

WO2011069761

 Figure imgf000037_0001






Example 2
2-(Difluoromethyl)-4-(6-fluoro-3-methyl-lH-indazol-5-yl)-6-(4-fluorophenyl)-l,4-dihydropyridine- 3,5-dicarbonitrile
A mixture of 200 mg (0.569 mmol) (2ii)-2-(4-fluorobenzoyl)-3-(6-fluoro-3-methyl-lH-indazol-5-yl)- prop-2-enenitrile (Example 5A) and 69 mg (0.569 mmol) 3-amino-4,4-difluorobut-2-enenitrile [obtainable by Thorpe reaction of acetonitrile with 2,2-difluoroacetonitrile, cf. Org. React. 15, 1 (1967), ibid. 3J_, 1 (1984)] in 2-propanol (1 ml) was stirred at reflux for 12 h. Then, acetic acid (1.5 ml) was added, and stirring at reflux was continued for 6 h. Upon cooling, the mixture was concentrated under reduced pressure, and the residue was directly purified by preparative RP-HPLC (methanol/water + 0.1 % TFA gradient, final mixture 80:20 v/v) to yield 36 mg (15% of th.) of the racemic title compound. LC-MS (method 4): Rt = 0.97 min; MS (ESIpos): m/z = 424 (M+H)
'H-NMR (400 MHz, DMSO-dg): δ = 12.87 (br. s, 1H), 10.44 (s, 1H), 7.78 (d, 1H), 7.61 (m, 2H), 7.41-7.35 (m, 3H), 6.79 (t, 1H, F = 51.8 Hz), 5.08 (s, 1H), 2.54 (s, 3H) ppm.


 http://www.google.com/patents/WO2011069761A1?cl=en

 


Comparative Example B
2-(4-Fluorophenyl)-6-methyl-4-(3-methyl-lH-indazol-5-yl)-l,4-dihydropyridine-3,5-dicarbonitrile

A mixture of 200 mg (0.89 mmol) (2i?)-2-[(3-methyl-lH-indazol-5-yl)methylidene]-3-oxobutane- nitrile (Example 2A), 159 mg (0.98 mmol) 3-(4-fluorophenyl)-3-oxopropanenitrile and 205 mg (2.66 mmol) ammonium acetate in ethanol/acetic acid (4: 1 v/v, 1 1 ml) was heated to reflux overnight. After cooling, the reaction mixture was directly purified by preparative RP-HPLC (acetonitrile/water + 0.1% TFA gradient) to afford 136 mg (41% of th.) of the racemic title compound.
LC-MS (method 2): Rt = 1.04 min; MS (ESIpos): m/z = 370 (M+H)+
'H-NMR (400 MHz, DMSO-dg): δ = 12.70 (br. s, 1H), 9.74 (s, 1H), 7.64-7.59 (m, 3H), 7.53 (d, 1H), 7.40-7.33 (m, 3H), 4.68 (s, 1H), 2.48 (s, 3H), 2.11 (s, 3H) ppm.










DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Facebook FACEBOOK
Join me on twitterFollow amcrasto on Twitter     
Join me on google plus Googleplus

 amcrasto@gmail.com